SingVax licenses, acquires and collaborates with companies, to gain access to innovative technologies that enable the company to rapidly and efficiently develop improved vaccine products. Key technologies include:

PER.C6 Cell-line Technology
The PER.C6® human cell line technology is licensed by SingVax from Crucell. This is ideally suited for the development and large-scale manufacturing of SingVax's vaccines. Compared to conventional technologies, it has an excellent safety profile, scalability and productivity under serum-free culture conditions.



 

OctoPlus' proprietary drug delivery systems
Through a collaboration, SingVax and OctoPlus aim to develop a single shot JE vaccine. OctoPlus, the Dutch drug delivery and development company, has developed delivery systems that enable the controlled release of drugs and antigens. OctoPlus' proprietary innovative drug delivery systems are based on injectable, biodegradable microspheres.

Click here to see how the Octodex technology platform works.